北印度异基因造血细胞移植幸存者坚持长期随访预防措施的情况。

Blood cell therapy Pub Date : 2022-06-10 eCollection Date: 2022-08-25 DOI:10.31547/bct-2021-025
Niranjan S Khaire, Prashant Chhabra, Dikshat G Gupta, Aditya Jandial, Alka Khadwal, Kripa Shanker Kasudhan, Shaweta Kaundal, Madhu Chopra, Arihant Jain, Gaurav Prakash, Navneet S Majhail, Pankaj Malhotra, Deepesh P Lad
{"title":"北印度异基因造血细胞移植幸存者坚持长期随访预防措施的情况。","authors":"Niranjan S Khaire, Prashant Chhabra, Dikshat G Gupta, Aditya Jandial, Alka Khadwal, Kripa Shanker Kasudhan, Shaweta Kaundal, Madhu Chopra, Arihant Jain, Gaurav Prakash, Navneet S Majhail, Pankaj Malhotra, Deepesh P Lad","doi":"10.31547/bct-2021-025","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>There are existing international guidelines for long-term follow-up (LTFU) care of allogeneic hematopoietic cell transplantation (allo-HCT) survivors. However, implementing these guidelines represents a unique challenge in resource-challenged settings.</p><p><strong>Methods: </strong>This study aimed to evaluate adherence to recommended surveillance in allo-HCT survivors at an academic center in North India and study the incidence of late effects. This single-center, retrospective study analyzed records of allo-HCT recipients from 2016 to 2020. Survivors were screened in our LTFU clinic at day +100 and +365 using cardiometabolic parameters (screening for hypertension, dyslipidemia, hyperglycemia, 24-hour urine protein, thyroid function), pulmonary function test (PFT), bone mineral density (BMD), and initiation of revaccination.</p><p><strong>Results: </strong>A total of 40/80 (50%) allo-HCT survivors were alive at a median of 888 days (IQR 515-1,306). The adherence to home-based screening parameters such as blood pressure and blood glucose was highest (>75%), followed by lab-based parameters (45-70%), and lowest for specialized tests such as PFT (<50%) at both day +100 and +365 time points. Adherence to the initiation of revaccination was only 67%. At least one cardiometabolic parameter was out of range in 55% and 63% of survivors at day +100 and +365, respectively.</p><p><strong>Conclusion: </strong>The adherence to recommended surveillance measures for allo-HCT survivors in an academic LTFU clinic at one year was only 75% overall. Cardiometabolic abnormalities were noted in more than half of the survivors. This study emphasizes the need for a structured LTFU clinic in all centers performing HCT.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"5 3","pages":"83-86"},"PeriodicalIF":0.0000,"publicationDate":"2022-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/db/7b/2432-7026-5-3-0083.PMC9873420.pdf","citationCount":"0","resultStr":"{\"title\":\"Adherence to long-term follow-up preventive practices in allogeneic hematopoietic cell transplantation survivors from North India.\",\"authors\":\"Niranjan S Khaire, Prashant Chhabra, Dikshat G Gupta, Aditya Jandial, Alka Khadwal, Kripa Shanker Kasudhan, Shaweta Kaundal, Madhu Chopra, Arihant Jain, Gaurav Prakash, Navneet S Majhail, Pankaj Malhotra, Deepesh P Lad\",\"doi\":\"10.31547/bct-2021-025\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>There are existing international guidelines for long-term follow-up (LTFU) care of allogeneic hematopoietic cell transplantation (allo-HCT) survivors. However, implementing these guidelines represents a unique challenge in resource-challenged settings.</p><p><strong>Methods: </strong>This study aimed to evaluate adherence to recommended surveillance in allo-HCT survivors at an academic center in North India and study the incidence of late effects. This single-center, retrospective study analyzed records of allo-HCT recipients from 2016 to 2020. Survivors were screened in our LTFU clinic at day +100 and +365 using cardiometabolic parameters (screening for hypertension, dyslipidemia, hyperglycemia, 24-hour urine protein, thyroid function), pulmonary function test (PFT), bone mineral density (BMD), and initiation of revaccination.</p><p><strong>Results: </strong>A total of 40/80 (50%) allo-HCT survivors were alive at a median of 888 days (IQR 515-1,306). The adherence to home-based screening parameters such as blood pressure and blood glucose was highest (>75%), followed by lab-based parameters (45-70%), and lowest for specialized tests such as PFT (<50%) at both day +100 and +365 time points. Adherence to the initiation of revaccination was only 67%. At least one cardiometabolic parameter was out of range in 55% and 63% of survivors at day +100 and +365, respectively.</p><p><strong>Conclusion: </strong>The adherence to recommended surveillance measures for allo-HCT survivors in an academic LTFU clinic at one year was only 75% overall. Cardiometabolic abnormalities were noted in more than half of the survivors. This study emphasizes the need for a structured LTFU clinic in all centers performing HCT.</p>\",\"PeriodicalId\":72423,\"journal\":{\"name\":\"Blood cell therapy\",\"volume\":\"5 3\",\"pages\":\"83-86\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-06-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/db/7b/2432-7026-5-3-0083.PMC9873420.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood cell therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31547/bct-2021-025\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/8/25 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood cell therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31547/bct-2021-025","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/8/25 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

导言:异基因造血细胞移植(allo-HCT)幸存者的长期随访(LTFU)护理已有国际指南。然而,在资源匮乏的环境中实施这些指南是一项独特的挑战:本研究旨在评估北印度一家学术中心对异体造血干细胞移植幸存者进行推荐监护的遵守情况,并研究晚期效应的发生率。这项单中心回顾性研究分析了 2016 年至 2020 年间接受异体肝移植者的记录。我们的LTFU门诊在第100天和第365天对幸存者进行了心血管代谢指标(筛查高血压、血脂异常、高血糖、24小时尿蛋白、甲状腺功能)、肺功能测试(PFT)、骨矿物质密度(BMD)和开始重新接种疫苗的筛查:共有 40/80 例(50%)异体肝移植幸存者在中位数为 888 天(IQR 515-1306 天)时存活。对血压和血糖等家庭筛查指标的依从性最高(>75%),其次是实验室指标(45%-70%),而对心电图等专业检查的依从性最低:在一家学术性 LTFU 诊所,对异体肝移植存活者一年后采取推荐监测措施的比例总体上仅为 75%。超过一半的幸存者出现了心脏代谢异常。这项研究强调,所有进行 HCT 的中心都有必要设立结构化的 LTFU 诊所。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Adherence to long-term follow-up preventive practices in allogeneic hematopoietic cell transplantation survivors from North India.

Introduction: There are existing international guidelines for long-term follow-up (LTFU) care of allogeneic hematopoietic cell transplantation (allo-HCT) survivors. However, implementing these guidelines represents a unique challenge in resource-challenged settings.

Methods: This study aimed to evaluate adherence to recommended surveillance in allo-HCT survivors at an academic center in North India and study the incidence of late effects. This single-center, retrospective study analyzed records of allo-HCT recipients from 2016 to 2020. Survivors were screened in our LTFU clinic at day +100 and +365 using cardiometabolic parameters (screening for hypertension, dyslipidemia, hyperglycemia, 24-hour urine protein, thyroid function), pulmonary function test (PFT), bone mineral density (BMD), and initiation of revaccination.

Results: A total of 40/80 (50%) allo-HCT survivors were alive at a median of 888 days (IQR 515-1,306). The adherence to home-based screening parameters such as blood pressure and blood glucose was highest (>75%), followed by lab-based parameters (45-70%), and lowest for specialized tests such as PFT (<50%) at both day +100 and +365 time points. Adherence to the initiation of revaccination was only 67%. At least one cardiometabolic parameter was out of range in 55% and 63% of survivors at day +100 and +365, respectively.

Conclusion: The adherence to recommended surveillance measures for allo-HCT survivors in an academic LTFU clinic at one year was only 75% overall. Cardiometabolic abnormalities were noted in more than half of the survivors. This study emphasizes the need for a structured LTFU clinic in all centers performing HCT.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信